Bristol-Myers Squibb (BMY) Earnings Date & Reports

Key Takeaways

• Bristol-Myers Squibb delivered a decisive beat: adjusted earnings per share (EPS) of $2.04 versus the $1.60 consensus, a 27.5% surprise to the upside.
• Revenue surged past expectations: total revenue reached $12.97 billion, up 6% year-over-year and more than $1.2 billion above Wall Street forecasts.
• The Growth Portfolio now dominates: revenues from newer medicines rose 15% to $7.6 billion, representing nearly 60% of total company sales.
• Eliquis remained the powerhouse: the blood thinner generated approximately $4.5 billion in quarterly sales, up 21%, driven by strong demand and market share gains.
• Full-year 2026 guidance raised sharply: management lifted its revenue outlook to $49–$50 billion and adjusted EPS guidance to $6.75–$7.00, both well above prior Street estimates.

Earnings Context and Why It Matters

Bristol-Myers Squibb entered this earnings season at a pivotal moment in its corporate transformation. The company has been navigating a deliberate but challenging shift away from its Legacy Portfolio — older medicines facing generic competition, most notably the former blockbuster Revlimid — toward a new wave of high-growth therapies across oncology, cardiovascular, immunology, and neuroscience. Investors have closely tracked whether the Growth Portfolio could scale quickly enough to offset multi-billion-dollar revenue losses from patent expirations. This Q2 2026 report provided a resounding answer: the transition is not only working, it is accelerating. With the Growth Portfolio now approaching 60% of total revenue and management confident enough to raise annual guidance by billions of dollars, the quarter marked a defining moment for the company's multi-year turnaround narrative.

Reported Results

Bristol-Myers Squibb reported second-quarter 2026 total revenues of $12.97 billion, up 6% on a reported basis (5% excluding foreign exchange) from $12.27 billion in the prior-year period. This result crushed the analyst consensus estimate of approximately $11.71–$11.74 billion. On the bottom line, adjusted diluted EPS came in at $2.04, a 40% increase from $1.46 a year ago and well ahead of the $1.59–$1.61 consensus. GAAP (Generally Accepted Accounting Principles) EPS was $1.62, compared to $0.64 in Q2 2025, with the large GAAP swing reflecting the absence of significant acquired IPRD (in-process research and development) charges that weighed on the prior-year period.

The Growth Portfolio was the standout, generating $7.6 billion in revenue — a 15% increase year-over-year. Key contributors included Camzyos (up 59% to $416 million), Breyanzi (up 41% to $484 million), Reblozyl (up 29% to $735 million), and Opdivo Qvantig, the faster-administered subcutaneous formulation of the blockbuster immunotherapy, which reached $261 million and is now annualizing at over $1 billion. Eliquis, classified within the Legacy Portfolio, continued to defy expectations with 21% growth to $4.5 billion, driven by dominant market share in the anticoagulant space. The Legacy Portfolio overall declined 4% to $5.4 billion, as generic erosion on products such as Revlimid (down 49% to $425 million) continued, albeit at a manageable pace.

Gross margin came in at 71.4%, slightly lower than 72.6% a year ago due to product mix shifts. Operating expenses totaled $4.1 billion. The company generated $3.4 billion in operating cash flow during the quarter and held $11.5 billion in cash and marketable securities as of June 30, 2026.

Management also raised its full-year 2026 guidance materially. Revenue is now expected in the range of $49 billion to $50 billion, up from $46–$47.5 billion. Adjusted EPS guidance jumped to $6.75–$7.00, up from $6.05–$6.35. Both ranges sit comfortably above the prevailing analyst consensus at the time of the report.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors efficiently filter the market using a broad range of quantitative criteria. The platform allows users to scan thousands of stocks and ETFs based on technical patterns, fundamental metrics, volatility profiles, trend signals, and proprietary AI-driven ratings. Customizable filters — including industry, market capitalization, price patterns, and performance indicators — make it possible to surface trade ideas, breakout candidates, and emerging trends far more effectively than manual screening. For investors following pharmaceutical names like Bristol-Myers Squibb, the AI Screener offers a streamlined way to monitor sector-wide momentum and identify comparable opportunities as industry dynamics evolve.

Market Reaction and Investor Sentiment

Bristol-Myers Squibb shares responded positively to the earnings release, closing at $64.86 on July 30, 2026, a gain of 2.79% for the session. The stock traded as high as $65.11 intraday, pushing against its 52-week high of approximately $65.22. The rally reflected broad investor approval of the magnitude of the beat and the decisive guidance raise. Heading into the report, sentiment had been cautiously optimistic — BMY shares had already gained roughly 17% year-to-date, outpacing the broader S&P 500, and the stock was trading near the top of its 52-week range of $42.52–$65.22. The fact that shares still managed to advance nearly 3% on results that were already partly anticipated by the market's prior run-up underscores the strength of the underlying numbers. Analyst consensus remains at Hold, with a mix of Buy and Hold ratings, suggesting that while the quarter was impressive, some on the Street are waiting for further pipeline execution before turning more bullish.

Forward Outlook and Key Factors to Monitor

Looking ahead, Bristol-Myers Squibb's raised guidance signals management's confidence that the Growth Portfolio's momentum is sustainable through the second half of 2026. The projected Eliquis revenue growth of 20–25% for the full year — up sharply from the prior 10–15% forecast — suggests the anticoagulant franchise has significantly more runway than many analysts had modeled. Investors should monitor whether this growth trajectory holds as the year progresses and whether the Legacy Portfolio's decline remains contained within the projected 4–6% range.

Pipeline catalysts represent the next major value driver. The FDA (U.S. Food and Drug Administration) decision on iberdomide, a CELMoD (cereblon E3 ligase modulator) therapy for multiple myeloma, is expected by August 17, 2026, with mezigdomide's PDUFA (Prescription Drug User Fee Act) date set for May 2027. These represent the company's bet on protein degradation as a next-generation oncology platform. Additionally, key clinical readouts for milvexian in secondary stroke prevention, Sotyktu in lupus, and amilparant are expected in late 2026, each carrying multibillion-dollar peak sales potential.

On the cost side, operating expense guidance edged up to $16.5 billion as the company invests in pre-launch activities and pipeline advancement. Gross margin, guided to 69–70% for the full year, will bear watching as product mix continues to shift toward newer therapies. With $11.5 billion in cash, the company retains significant flexibility for business development and shareholder returns, including a quarterly dividend yielding approximately 4%. The balance between reinvestment in the pipeline and capital returns will remain a key theme for investors evaluating BMY's long-term value proposition.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations